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The role of nitric oxide (NO) as a bronchodilator has been studied in humans with controversial results. 
The aim of the present study was to investigate the role of endogenous NO on bronchial tone by studying 
whether nitric oxide synthase (NOS) inhibition with NGnitro-L-arginine-methyl-ester (L-NAME) 
influences basal bronchial tone, or potentiates methacholine-induced bronchoconstriction. In a prelimi- 
nary experiment in five subjects, a significant reduction in exhaled NO was found after delivering 
L-NAME (15 mg in saline) (from 3.9 f 1.2 to 2.4 i 1.1 nmol min-l, PcO.05). In nine healthy 
non-smokers, specific airway conductance (SGAW), as a measure of airway calibre, was recorded after 
delivering, in a double-blind, controlled vs. placebo fashion, both nebulized L-NAME and saline, at 
baseline and after methacholine-induced bronchoconstriction. There was no significant difference 
between the baseline SGAW values before and after delivering L-NAME (0.264 f 0.04 and 
0.267 i 0.05 cm H,O - ’ s ~ ‘, respectively). 
After pre-treatment with L-NAME, SGAW values during methacholine-induced bronchoconstriction 
were not different in comparison to values obtained after saline inhalation. 
It is concluded that decreased endogenous NO does not influence bronchial tone in healthy people, nor 
does it modify methacholine-induced bronchoconstriction. 
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Introduction 
Nitric oxide (NO) is formed by many different 
cells within the lung (1). These include endo- 
thelial, epithelial, neural and inflammatory cells. 
Endothelial NO is important in regulating 
pulmonary vascular resistance (2). 
In human airways, neural NO released during 
electrical field stimulation is proposed to relax 
airway smooth muscle (3). Indeed, inhaled NO 
can reduce airway smooth muscle (3). Indeed, 
inhaled NO can reduce airway resistance in 
rabbits (4), guinea pigs (5) and, to a lesser extent, 
humans (6). This has led to the notion that 
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airway tone might be modulated by endogenous 
NO release (7). 
If this is the case, the inhibition of NO pro- 
duction would be expected to alter airway tone. 
1n vivo, NO can be detected in the exhaled air, 
allowing a measure of its production rate (8). 
The aim of the present study was: (i) to 
investigate the effect of an aerosolized inhibitor 
of NO synthase (NOS) NGnitro-L-arginine- 
methyl-ester (L-NAME) on NO production; and 
(ii) to evaluate whether L-NAME inhalation 
influences basal bronchial tone or potentiates 
methacholine-induced bronchoconstriction. 
Materials and Methods 
SUBJECTS 
Nine healthy non-smoking subjects (five males, 
four females) recruited from hospital medical 
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TABLE 1. Subject characteristics 
Methacholine 
Sub- FEV, PC*, 
jects Sex Age (% pred.) (mg ml - ‘) Atopy 
1 F 33 101 
2 F 29 114 
3 F 30 90 
4 M 40 104 
5 M 34 92 
6 M 27 99 
7 F 32 107 
8 M 26 102 










M, male; F, female; FEV,, forced expired volume 
in 1 s; methacholine PC,,, provocative concentration 
of methacholine leading to 20% fall from baseline 
FEV, 
personnel took part in the study (Table 1). 
Subjects were assessed for evidence of atopy by 
symptom questionnaire, total serum IgE and 
skin-prick testing with common allergens, and 
were excluded if they had a history of asthma, 
recent respiratory infection or an increase of 
airway resistance after inhaling saline diluent. 
Atopy was defined by a serum IgE >2 standard 
deviations (SD) above the mean for normal 
population, a skin-prick test >I mm than 
negative control, or both. All subjects had a 
spirometric methacholine (MCh) challenge test, 
and their PC,, resulted > 16 mg ml ~ ‘. The 
subjects gave their informed written consent and 
the study was approved by the local Ethics 
Committee. 
EXPERIMENT 1 
As a preliminary experiment, the effect of aero- 
solized NOS inhibitor L-NAME on the levels of 
exhaled NO was studied in five subjects. The 
concentration of exhaled NO was measured 
by chemiluminescence (Model 42, Therm0 
Electron, Warrington, U.K.) as described 
previously (9). Calibration was performed with 
certified gas concentrations (British Oxigen 
Company) before each study. The subjects, 
wearing a nose clip, breathed through a two-way 
non-return valve. The inhaled gas, NO-free 
air (Specialist gases BOC), was held in a 100 1 
Douglas bag connected to the two-way valve. 
The exhaled air was collected in a further 100 1 
Douglas bag connected via a mixing box and 
pneumotachograph to the other port of the two- 
way valve. The pneumotachograph and differen- 
tial transducer (PK Morgan Gillingham, U.K.) 
were used to measure the minute volume (MV). 
The exhaled air was collected over a period of 
5 min of quiet breathing. Nitric oxide concen- 
tration was measured from the total mixed 
exhaled volume. The production rate was calcu- 
lated by multiplying this concentration of NO in 
ppb by the MV, and dividing the product by 
24.04 which is the volume occupied by one mole 
of gas at atmospheric temperature and pressure. 
The NO measurements were assessed at 5, 10, 
15, 25, 35 and 40 min after the delivery of 
L-NAME (Sigma, U.K.) (15 mg) in normal 
saline and after normal saline alone. The dose 
of L-NAME was chosen after assessing the 
response to various doses of L-NAME ranging 
from 1 to 15 mg. The drugs were delivered by 
a nebulizer (De Vilbiss, Somerset, PA, U.S.A.) 
over a period of 10 min breathing at tidal 
volume. 
EXPERIMENT 2 
Airway resistance, expressed as specific airway 
conductance (SGAW), was used to quantify 
changes in airway calibre. These were measured 
with a compensated whole-body plethysmo- 
graph (Sensor Medics, 6200 Autobox). The 
measurements were made in triplicate with the 
subjects panting at 2 Hz. 
Aerosols of MCh (Lofarma, Italy), in saline 
solution prepared immediately before use, were 
generated by a jet nebulizer (Dosimeter MB3, 
MEFAR Electromedical, Italy) with an output 
of 1Oyl puff-l. The aerosol was inhaled 
through the mouth from the outlet of the 
nebulizer during a l-s inspiratory manoeuvre 
from functional residual capacity to total lung 
capacity, and a subsequent 6 s breathhold. Sue-’ 
cessive concentrations of MCh (432 mg ml - ‘) 
were inhaled (using doubling cumulative 
challenge technique) with the purpose of 
decreasing SGAW to at least 65% of the baseline 
value. 
NITRIC OXIDE INHIBITION AND HUMAN BRONCHIAL TONE 337 
TABLE 2. Time-response curve of exhaled nitric oxide (NO) production and concentration for each of five subjects 
after aerosolized NGnitro-L-arginine-methyl-ester (L-NAME) (15 mg) 
Pre-L-NAME 5 10 15 25 35 40 
Exhaled NO production (nmol min - ‘) 
Subject 1 5.9 4.4 4.5 3.5 3.8 4.2 3.6 
Subject 2 3.4 2.0 1.8 1.8 2.0 2.0 1.9 
Subject 3 3.3 2.4 2.4 1.7 2.0 2.5 2.2 
Subject 4 3.0 1.9 2.0 2.5 2.6 2.0 1.8 
Subject 5 3.7 1.5 2.3 1.7 1.9 1.8 2.2 
Mean i SD 3.8 It 1.2 2.4 i 1.1” 2.6 it l.l* 2.2 It 0.8’” 2.5 i 0.8” 2.5 i 1.0”: 2.3 i 0.7” 
Exhaled NO concentration (ppb) 
Subject 1 15.6 9.3 
Subject 2 8.9 5.7 
Subject 3 12.8 6.7 
Subject 4 11.9 8.7 
Subject 5 12.5 6.2 
Mean i SD 12.3 i 2.4 7.3 f 1.6” 
11.2 10.8 11.4 11.8 12.0 
6.0 5.6 7.0 7.2 8-O 
9.5 6.6 7.5 94 7.1 
8.5 7.8 8.6 7.8 7.4 
6.8 7.1 8.4 7.3 8.7 
8.4 i 2.1” 7.6 i 2.0” 8.6 f 1.7” 8.7 zt 1.9” 8.6 It 2.0” 
ppb, parts per billion; "P~O.005 
Each of the nine subjects was studied on two 
separate days. On each visit, after measurements 
of lung function variables (Vitalograph, U.K.), 
the patients were treated, in a double-blind con- 
trolled vs placebo fashion, either with saline 
0.9% NaCl (placebo) or L-NAME (15 mg in 
saline). The drugs were delivered by a nebulizer 
as described in Experiment 1 prior to triplicate 
SGAW measurement. Methacholine challenges 
were performed 5 min after the pre-treatment 
with both saline and L-NAME, and SGAW 
was measured 3 min after the inhalation of 
buffer control solutions and successive MCh 
concentrations. The dose-response curve for 
methacholine was completed during 40 min of 
L-NAME having an effect. 
Statistical analysis was performed using 
Student’s t-test for unpaired data, and the 
time-response curves were tested with analysis 
of variance (ANOVA) for repeated measures. 
Results are given as mean values & SD of mean. 
A value of PcO.05 was considered statistically 
significant. 
Results 
Nitric oxide expired production decreased 5 min 
after the inhalation of 1, 7.5 and 15 mg of 
L-NAME, from 3.5 & 1.2 to 3.21 I.1 (n=3), 
from 3.1 f 0.4 to 2.3 It 0.5 (n= 3) and from 
3.9 + 1.2 to 2.4i I.1 mmol mint (12=5; 
P<O+O5), respectively. The effect of L-NAME 
lasted over 40 min in each subject (Table 2). 
Expired NO did not change after inhalation of 
placebo in comparison to basal values. 
The inhalation of L-NAME or placebo did 
not cause a significant change of SGAW 
(0.264 f 0.04 to 0.267 f O-05 and 0.260 * 0.06 to 
0.271 f 0.04 cm H,O - ’ s - ’ NS, respectively). 
The MCh challenge caused a decrease >35% of 
SGAW in all subjects. The decrease of SGAW 
during MCh challenge did not differ significantly 
with either L-NAME or placebo pre-treatment 
(Fig. 1). 
Discussion 
This study has shown that the aerosolization 
of L-NAME, an inhibitor of NQS, at doses 
capable of decreasing NO levels on exhaled air, 
has no effect on the bronchial resting tone, 
nor does it modify the bronchial response 
to inhaled MCh in healthy non-smokers. As 
reviewed recently (I), several cell types are a 
potential source of endogenous NO in the lung; 
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among others, NOS-containing nerve fibres, 
densest in smooth muscle layer, and epithelium 
in the bronchial tree could release NO, thus 
contributing to bronchial tone. In fact, pre- 
vious in vitro studies have suggested NO may 
play a role in modulating both excitatory 
(cholinergic) (10) and inhibitory (non- 
adrenergic, non-cholinergic, NANC) bronchial 
response (3). However, these only provide indi- 
rect evidence of the contribution of endogenous 
NO in the regulation of bronchial tone. Sanna 
et al. (6) have demonstrated a significant 
bronchodilator effect of NO in men after 
MCh-induced bronchospasm, but the effect 
was much less than that observed after the 
inhalation of /3-sympatomimetic drugs. They 
also failed to demonstrate any change in 
baseline SGAW after NO inhalation. 
The present study has looked at the effect of 
inhibiting NO synthesis on baseline airways 
calibre and during MCh-induced bronchocon- 
striction. By aerosol, an inhibitor of NO produc- 
tion, namely L-NAME, was delivered that has 
been utilized as an aerosol in an animal model by 
Nijkamp et al. (11). L-NAME administration 
significantly decreased NO levels in the exhaled 
air in comparison to placebo. Recently, Yates 
et al. (12) examined the effects of the inhalation 
of a NOS inhibitor L-NMMA on expired NO 
in humans, showing a percentage of reduction 
of NO production comparable to the present 
study. 
The change of airway resistance, expressed 
as specific conductance, was measured before 
and after MCh-induced bronchoconstriction. In 
animals, it has been reported that NO exerts 
its effect predominantly on large airways (4). On 
the other hand, NOS immunostaining has been 
demonstrated mainly in the epithelium from the 
large airway in humans (13). Therefore, it is 
likely that measurement of airway resistance 
could have detected changes sensitively in the 
calibre of large airways due to NO inhibition. 
No change in airway calibre was found with 
L-NAME. Furthermore, the NOS inhibitor did 
not cause any change in bronchial reactivity 
to MCh. 
The route of administration was found to 
reduce the NO production significantly in all 
subjects, so it is unlikely that inefficient depo- 
sition of L-NAME was a factor responsible for 
a lack of the effect on bronchial reactivity to 
MCh. The absence of modification of bronchial 
reactivity after L-NAME might suggest that 
NO does not contribute to basal airway tone 
and basal degree of airway responsiveness. 
On the other hand, the limited effect of 
L-NAME on exhaled NO does not allow 
exclusion of a marginal influence of NO on 
bronchial tone. 
The endogenous NO contribution to choliner- 
gic neurotransmission in human airways is not 
completely understood. In guinea pigs (1 1), NOS 
inhibition resulted in a marked increase in 
airway contraction after stimulation with hista- 
mine, but resulted in a variable response to 
cholinergic agonists carbachol, MCh or arecho- 
lin. In another in vivo study in dogs (14), 
et al. have shown that inhaled NO (which com- 
pletely reverses histamine-induced airway con- 
striction) only partially reversed MCh-induced 
constriction indicating a lesser contribution of 
NO in the direct modulation of neural choliner- 
gic pathway. Furthermore, in rat, the NO 
inhibition enhances bronchial reactivity to 
bradykinin whereas it does not modify the 
response to MCh (15). 
The inhibition of constitutive NO synthesis 
by L-NAME does not influence either basal 
tone or the responsiveness to MCh, although 
L-NAME inhibition of endotoxin-stimulated 
inducible NO synthesis blocked the endo- 
toxin-induced bronchial hyper-responsiveness 
(16). The present results obtained in healthy 
non-smokers do not apply to other con- 
ditions in which acute airway infection (17) or 
chronic airway inflammation (18) could 
increase exhaled NO, reflecting expression of 
inducible NOS in airway epithelial cells when 
these are stimulated by pro-inflammatory 
cytokines (19). Thus, abnormalities in NO pro- 
duction could contribute to modification of the 
bronchial response to bronchoconstrictors. 
Noticeably, in asthmatics, the inhalation of 
L-NMMA could increase the bronchial 
response to bradykinin and, to a lesser extent, 
to MCh (18). 
Nevertheless, in healthy subjects, the reduc- 
tion of endogenous NO release in the airway 
does not influence bronchial tone, nor does it 
modify the bronchoconstrictive response to 
MCh. 
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